We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Alliance for Neurodegenerative Diagnostics

By Labmedica staff writers
Posted on 08 Apr 2005
A collaborative research agreement has been announced by Power3 Medical Products, Inc. (The Woodlands, TX, USA) and New Horizons Diagnostics Corp. (Columbia, MD, USA) for the development of antibody-based diagnostic tests for neurodegenerative disease, using the protein biomarkers of Power3 Medical.

Power3 has discovered a method of employing a series of tests for the differential diagnosis of neurodegenerative diseases utilizing blood serum, which was co-developed by neurologist Dr. Stan Appel, professor of neurology at Baylor College of Medicine (Houston, TX, USA), Dr. Ira L. Goldknopf, chief scientific officer of Power3 Medical, and their respective teams.

Power3 Medical intends to develop a series of tests that involve monitoring the concentration of panels of proteins in the blood. The company has discovered unique groups of biomarkers whose profiles are relatively sensitive and specific in distinguishing patients with amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease from each other, as well as from normal patients and patients with other neurologic disorders. In all, Power3 has identified 34 biomarkers for neurodegenerative diseases.

New Horizons Diagnostics will utilize specifically tailored monoclonal and polyclonal antibodies to the biomarkers, which will be incorporated into immunoassays. Once the assays are available, New Horizons will then develop and validate diagnostic tests on their platform, which is specifically designed to detect and discriminate among the neurodegenerative diseases.

"New Horizons Diagnostics has been successfully involved in test platform development before, but none of these projects are as important or timely as the collaboration with Power3,” observed Lawrence Loomis, president of New Horizons. "With an aging population and new therapies available, early detection is paramount. We are excited to have been chosen to be part of this elite team to make a new age of diagnostics available.”



Related Links:
Power3 Medical
New Horizons

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT

Latest Industry News

Qiagen Agrees to Go Private Through EQT-Led Acquisition
08 Apr 2005  |   Industry

Hologic and Inpeco Partner to Advance Molecular Laboratory Automation in Europe
08 Apr 2005  |   Industry

Collaboration to Expand Cervical Cancer Screening Access With At-Home HPV Collection
08 Apr 2005  |   Industry